Even as chances of reinfection with Covid-19 are low, vaccination against Covid-19 is likely to protect people from severe symptoms if a fresh infection occurs after the immunity from the vaccine lapses, says AIIMS director Dr Randeep Guleria.
Even as the UK has become the first country to authorise a vaccine against Covid-19, India continues to look at the Oxford-AstraZeneca shot along with some other Indian candidates as its choice against the pandemic.
As the national expert group on Covid-19 vaccine firms up plans for procurement and distribution of shots, the Centre is betting on the five vaccine candidates that are currently undergoing clinical trials in India.
The Ministry of Health and Family Welfare said on Tuesday that one of the three COVID-19 vaccine candidates would enter the third phase of the pre-clinical human trial by Wednesday.
The race for an indigenous vaccine against the novel coronavirus is on in earnest. Human trials using the vaccine candidates of two companies — Bharat Biotech and Zydus Cadila — are currently on in six cities in as many states.
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
